Chronic Venous Insufficiency Market Insights Highlight Expanding Outlook Till 2034, DelveInsight Evaluates

DelveInsight's "Chronic Venous Insufficiency Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Chronic Venous Insufficiency, historical and forecasted epidemiology as well as the Chronic Venous Insufficiency market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Chronic Venous Insufficiency market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Chronic Venous Insufficiency Market Forecast
https://www.delveinsight.com/sample-request/chronic-venous-insufficiency-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key facts of the Chronic Venous Insufficiency Market Report:
• The Chronic Venous Insufficiency market size across the 7MM was valued at USD 2,652 million in 2025 and is expected to expand at a CAGR of 9.5%, reaching approximately USD 5,951 million by 2034.
• In September 2025, enVVeno Medical Corporation (Nasdaq: NVNO) stated that it intends to submit a supervisory appeal following the not-approvable letter issued by the U.S. FDA's Center for Devices and Radiological Health (CDRH). The letter, dated August 19, 2025, was issued in response to the company's Premarket Approval (PMA) application for VenoValve®, a surgical venous valve implant developed to address severe deep chronic venous insufficiency (CVI).
• In August 2025, enVVeno Medical Corporation reported that the FDA has issued a not-approvable letter for its Premarket Approval (PMA) application for VenoValve®, a surgically implanted replacement venous valve intended for patients with severe deep chronic venous insufficiency (CVI).
• In July 2025, TR Therapeutics shared findings from a Phase 3 randomized, double-blind, parallel-group study assessing the efficacy, tolerability, and safety of TR987® 0.1% Gel compared to the standard of care for treating leg ulcers caused by chronic venous insufficiency.
• In October 2024, InterVene, Inc., a clinical-stage medical device company focused on developing interventional treatments for chronic venous insufficiency (CVI), announced the successful completion of its $13 million Series A funding round. The investment was co-led by new investor Treo Ventures and existing investor RiverVest Venture Partners®. As part of the financing, Brad Vale, founding general partner at Treo Ventures, has joined InterVene's Board of Directors.
• In January 2024, VERIGRAFT achieved significant progress in its TECVI-1 first-in-man trial, having treated half of the participants. The trial reached the final regulatory safety milestone in early January and is showing sustained graft functionality 12 months after treatment.
• In March 2024, enVVeno Medical revealed positive topline efficacy data from the SAVVE US pivotal trial for the VenoValve, demonstrating notable clinical improvements. This data was presented at the 2024 American Venous Forum (AVF) Annual Meeting.
• The US Chronic Venous Insufficiency market was valued at roughly USD 1,200 million in 2023 and is projected to expand throughout the 2025-2034 forecast period.
• By 2034, Laser Ablation/Radiofrequency Ablation is expected to generate the highest revenue at about USD 1,787.9 million, while TR987 is forecasted to bring in the lowest revenue at approximately USD 20.3 million across the 7MM.
• Across the 7MM, there were roughly 17.64 million diagnosed cases of chronic venous insufficiency (CVI) in 2020, and this number is projected to grow at a CAGR of 1.4% through 2034.
• In the US, the prevalence was notably higher in women, with about 4,900 cases compared to 1,600 in men, and these figures are expected to rise over the 2025-2034 forecast period.
• Additionally, the US recorded around 52.1 million diagnosed cases of chronic venous disease (CVD) in 2020, a number anticipated to reach nearly 64.93 million by 2034, increasing at a CAGR of 1.6%. In 2023, women continued to represent the majority of CVI cases in the US.
• Key Chronic Venous Insufficiency Companies: enVVeno Medical Corporation, Verigraft, MediWound, TissueTech/Amniox Medical, Alfasigma S.p.A, Boehringer Ingelheim, Takeda, Abbott, Servier, Ten Sun Pharma Company, Pfizer, AstraZeneca, JMI Laboratories, and others
• Key Chronic Venous Insufficiency Therapies: VenoValve, P-TEV, EscharEx, TTAX01, Vessel, Antistax®, Coumarin/troxerutin, Venocur Triplex®, Detralex, Esarin Gel, Sirolimus, ticagrelor, Neutrolin, and others
• The Chronic Venous Insufficiency epidemiology based on gender analyzed that Chronic Venous Insufficiency is more common in women than men.
• The Chronic Venous Insufficiency market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Chronic Venous Insufficiency pipeline products will significantly revolutionize the Chronic Venous Insufficiency market dynamics.

Chronic Venous Insufficiency Overview
Chronic Venous Insufficiency (CVI) is a condition where the veins in the legs are unable to efficiently return blood to the heart, causing blood to pool in the veins. This can result in symptoms like swelling, varicose veins, pain, and skin changes. CVI is often caused by weakened or damaged vein valves, which allow blood to flow backward and accumulate. It is commonly associated with factors like aging, obesity, pregnancy, and prolonged standing or sitting. If left untreated, CVI can lead to complications such as ulcers or blood clots.

Get a Free sample for the Chronic Venous Insufficiency Market Forecast, Size & Share Analysis Report:
https://www.delveinsight.com/report-store/chronic-venous-insufficiency-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Chronic Venous Insufficiency Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Chronic Venous Insufficiency Epidemiology Segmentation:
The Chronic Venous Insufficiency market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
• Total Prevalent Cases of Chronic Venous Insufficiency in the 7MM
• Gender-specific Cases of Chronic Venous Insufficiency in the 7MM
• Age-specific Cases of Chronic Venous Insufficiency in the 7MM
• Treatable Cases of Chronic Venous Insufficiency in the 7MM

Download the report to understand which factors are driving Chronic Venous Insufficiency epidemiology trends @ Chronic Venous Insufficiency Epidemiology Forecast
https://www.delveinsight.com/sample-request/chronic-venous-insufficiency-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Chronic Venous Insufficiency Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Chronic Venous Insufficiency market or expected to get launched during the study period. The analysis covers Chronic Venous Insufficiency market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Chronic Venous Insufficiency Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Chronic Venous Insufficiency Therapies and Key Companies
• VenoValve: enVVeno Medical Corporation
• P-TEV: Verigraft
• EscharEx: MediWound
• TTAX01: TissueTech/Amniox Medical
• Vessel: Alfasigma S.p.A
• Antistax®: Boehringer Ingelheim
• Coumarin/troxerutin: Takeda
• Venocur Triplex®: Abbott
• Detralex: Servier
• Esarin Gel: Ten Sun Pharma Company
• Sirolimus: Pfizer
• ticagrelor: AstraZeneca
• Neutrolin: JMI Laboratories

Discover more about therapies set to grab major Chronic Venous Insufficiency market share @ Chronic Venous Insufficiency Treatment Landscape
https://www.delveinsight.com/sample-request/chronic-venous-insufficiency-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Chronic Venous Insufficiency Market Drivers
• Rising Prevalence Due to Aging Population & Sedentary Lifestyles: Increased cases linked to obesity, prolonged sitting/standing, and growing elderly population are expanding the patient base.
• Growing Adoption of Minimally Invasive Treatment Options: Rising preference for procedures like endovenous laser therapy, radiofrequency ablation, and sclerotherapy is boosting market growth.
• Technological Advancements in Diagnostic and Therapeutic Devices: Improved vascular imaging tools, compression systems, and catheter-based technologies are enhancing clinical outcomes and driving demand.
• Increasing Awareness and Early Diagnosis Efforts: More screening programs, public health campaigns, and physician education are accelerating treatment rates.
• Rising Healthcare Expenditure and Access to Vascular Care: Better reimbursement frameworks and expanding specialty clinics support overall market expansion.

Chronic Venous Insufficiency Market Barriers
• High Treatment Costs and Limited Reimbursement in Some Regions: Advanced vein procedures and long-term care products can be expensive, restricting patient access in low-income markets.
• Shortage of Skilled Vascular Specialists & Uneven Healthcare Infrastructure: Limited access to trained professionals, especially in rural and developing regions, slows adoption of advanced therapies.
• Underdiagnosis and Lack of Disease Awareness Among Patients: Many early-stage CVI cases go untreated due to misdiagnosis or perception that symptoms are cosmetic rather than medical.
• Risk of Complications and Recurrence After Treatment: Post-procedural complications such as thrombosis, nerve injury, or need for repeat interventions affect patient and physician confidence.
• Competition from Low-Cost Conservative Management: Widespread use of compression stockings and lifestyle-based management reduces demand for higher-priced interventional therapies.

Scope of the Chronic Venous Insufficiency Market Report
• Study Period: 2020-2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Chronic Venous Insufficiency Companies: enVVeno Medical Corporation, Verigraft, MediWound, TissueTech/Amniox Medical, Alfasigma S.p.A, Boehringer Ingelheim, Takeda, Abbott, Servier, Ten Sun Pharma Company, Pfizer, AstraZeneca, JMI Laboratories, and others
• Key Chronic Venous Insufficiency Therapies: VenoValve, P-TEV, EscharEx, TTAX01, Vessel, Antistax®, Coumarin/troxerutin, Venocur Triplex®, Detralex, Esarin Gel, Sirolimus, ticagrelor, Neutrolin, and others
• Chronic Venous Insufficiency Therapeutic Assessment: Chronic Venous Insufficiency current marketed and Chronic Venous Insufficiency emerging therapies
• Chronic Venous Insufficiency Market Dynamics: Chronic Venous Insufficiency market drivers and Chronic Venous Insufficiency market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Chronic Venous Insufficiency Unmet Needs, KOL's views, Analyst's views, Chronic Venous Insufficiency Market Access and Reimbursement

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
Contact No.: +14699457679
City: 304 S. Jones Blvd #2432, Las Vegas
State: Nevada (89107)
Country: United States
Website: https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.